Luteinizing hormone measurement in polycystic ovary syndrome: a practical approach.
The biological diagnosis of polycystic ovary syndrome (PCO) remains questionable, and a single immunological hLH (ihLH) determination can be misleading. In order better to characterize these patients, we studied hLH pulsatility every 10 min for 4h using a radioimmunoassay and then compared the results with others we obtained with a biological method. Radioimmunological and biological profiles were similar in patients with PCO and in controls. We also studied pulsatility characteristics - frequency and amplitude - and calculated the area under the curve (AUC). There was no significant increase in frequency in our 10 patients with PCO but, as in other studies, increased amplitude of hLH pulses was observed. The most discriminating parameter was the AUC. For practical purposes, we propose that hLH in patients with PCO could be assessed efficiently by taking four samples every 10 min, with computerized calculation of the AUC.
Collet
C
C
Service de Médecine Nucléaire, CHU Bretonneau, Tours, France.
Lecomte
P
P
Guilloteau
D
D
Lejeune
B
B
Lecomte
C
C
Besnard
J C
JC
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal; D019540:Area Under Curve; D001681:Biological Assay; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000175:diagnosis*; D011863:Radioimmunoassay; D012680:Sensitivity and Specificity
D000911:Antibodies, Monoclonal; D007986:Luteinizing Hormone